Novo Nordisk sets new pipeline and manufacturing ambitions

Novo Nordisk ($NVO) outlined ambitions to launch more than five major new medicines by 2030 and generate over DKK150 billion in risk-adjusted sales from its current pipeline by 2035. It also intends to enter or complete at least five Phase 3 programs in obesity and diabetes and at least five in other therapeutic areas.

The manufacturing plan calls for capacity to serve ten times more people with oral GLP-1 obesity treatments, while the broader group aims to reach more than 60 million patients by 2030. Novo targets adjusted revenue growth in line with peers and a broadly stable adjusted operating margin. These are explicitly strategic ambitions, not a replacement for financial guidance or guaranteed future sales.

Sources:

• Novo Nordisk — Capital Markets Day strategy release, GlobeNewswire via Investegate